Klumper is replacing Eric van der Putten who leaves his role as CEO to become Chief Business Development Officer, responsible for driving new business opportunities and growing SMS Oncology’s client base.
“Our clients will benefit discussing their new cancer studies with Eric who brings to the table 30+ years of experience in running phase I and II cancer trials in close collaboration with the top tier of oncologists,” said new CEO Edwin Klumper. “His experience and operational insights will be of great value to our clients in achieving their objectives.”
Merck Millipore appoints a new CEO, senior changes at Quintiles' Novella, and more.
Plus the latest on the AAIPHarma-CML merger.
People on the move in this week's column include executives from LabCorp, Quintiles and PDI, plus the...
This week's movers and shakers in outsourcing have joined PPD and Recipharm.
Clinipace, Novasep, Lonza and CRF Health are the contract organisations shaking up their senior management in this...